{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:20:15Z","timestamp":1783408815994,"version":"3.54.6"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177105"],"award-info":[{"award-number":["22177105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008327","name":"Zhejiang University of Technology","doi-asserted-by":"publisher","award":["KYY-HX-20240491"],"award-info":[{"award-number":["KYY-HX-20240491"]}],"id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118517","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:47:52Z","timestamp":1756482472000},"page":"118517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms"],"prefix":"10.1016","volume":"191","author":[{"given":"Jianwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoor","family":"Awadasseid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118517_bib1","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2025.118517_bib2","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: the new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118517_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biopha.2025.118517_bib4","doi-asserted-by":"crossref","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118517_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.drudis.2020.06.028","article-title":"Polymer\u2013drug conjugates: recent advances and future perspectives","volume":"25","author":"Thakor","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118517_bib7","article-title":"Development of methods for in vitro characterisation of antibody-drug conjugates","author":"Chapman","year":"2019","journal-title":"Univ. Bath."},{"key":"10.1016\/j.biopha.2025.118517_bib8","first-page":"1","article-title":"Recent advances in smart linkage strategies for developing drug conjugates for targeted delivery","volume":"383","author":"Zhang","year":"2025","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107078","article-title":"Antibody-drug conjugate [ADC] treatment of leukaemia","volume":"131","author":"Hassan","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2025.118517_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The clinical development of antibody\u2013drug conjugates\u2014lessons from leukaemia","volume":"18","author":"Jabbour","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2023.05.031","article-title":"Immune checkpoint-targeted drug conjugates: a promising tool for remodeling tumor immune microenvironment","volume":"359","author":"Choi","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118517_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.08.049","article-title":"Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy","volume":"142","author":"Joubert","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fphar.2019.00373","article-title":"The analysis of key factors related to ADCs structural design","volume":"10","author":"Tang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118517_bib14","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.3390\/molecules25122861","article-title":"Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: a drug-delivery perspective","volume":"25","author":"Dahlgren","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118517_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116522","article-title":"Implementation of antibody-drug conjugates in HER2-positive solid cancers: recent advances and future directions","volume":"174","author":"Yu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118517_bib16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118517_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118517_bib18","article-title":"Natural-source payloads used in the conjugated drugs architecture for cancer therapy: recent advances and future directions","author":"Li","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2025.118517_bib19","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118517_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118517_bib21","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2025.118517_bib22","first-page":"70","article-title":"The side effects of chemotherapeutic agents","volume":"19","author":"Carr","year":"2008","journal-title":"Curr. Anaesth. Crit. Care"},{"key":"10.1016\/j.biopha.2025.118517_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/BTT.S166310","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","author":"Cruz","year":"2019","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2023.2285996","article-title":"The endosomal-lysosomal system in ADC design and cancer therapy","volume":"23","author":"Leyton","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in Antibody\u2013Drug conjugates for cancer therapy: a new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118517_bib27","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118517_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2025.118517_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","article-title":"Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody\u2013drug conjugates and bispecific antibodies","volume":"191","author":"Torres","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2025.118517_bib30","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.7150\/thno.80901","article-title":"Smaller size packs a stronger punch-Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens","volume":"13","author":"Khilji","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118517_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118517_bib33","doi-asserted-by":"crossref","DOI":"10.4274\/MMJ.galenos.2023.29599","article-title":"Current advances and future prospects in cancer immunotherapeutics","volume":"38","author":"Dede","year":"2023","journal-title":"Medeni. Med. J."},{"key":"10.1016\/j.biopha.2025.118517_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2025.118517_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib36","article-title":"Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody\u2013drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2025.118517_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102552","article-title":"Advances in acid-degradable and enzyme-cleavable linkers for drug delivery","volume":"84","author":"Zhao","year":"2025","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118517_bib39","doi-asserted-by":"crossref","first-page":"1332539","DOI":"10.3389\/fphar.2023.1332539","article-title":"Advances in the study of marketed antibody-drug conjugates (ADCs) for the treatment of breast cancer","volume":"14","author":"Liang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118517_bib40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118517_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118517_bib42","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib43","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118517_bib44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/ijms26041440","article-title":"Advances in Antibody-Based Immune-Stimulating drugs: driving innovation in cancer therapy","volume":"26","author":"Zhao","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118517_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118517_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib47","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2025.118517_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105366","article-title":"Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation","volume":"116","author":"Xiao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib49","doi-asserted-by":"crossref","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","article-title":"Immune modulating antibody\u2013drug conjugate (IM-ADC) for cancer immunotherapy","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib50","article-title":"512 phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118517_bib51","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT227","article-title":"Abstract CT227: a phase 1 multiple ascending dose study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors","volume":"81","author":"Luke","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib52","article-title":"Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors","author":"Luke","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"10.1016\/j.biopha.2025.118517_bib53","first-page":"198","article-title":"Peptide drugs: a new direction in cancer immunotherapy","volume":"21","author":"Sui","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biopha.2025.118517_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113170","article-title":"Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1\/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation","volume":"213","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib55","doi-asserted-by":"crossref","first-page":"1230824","DOI":"10.3389\/fphar.2023.1230824","article-title":"Drug resistance mechanism and reversal strategy in lung cancer immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118517_bib56","first-page":"11","article-title":"Combining ADCs with immuno-oncology agents","author":"M\u00fcller","year":"2018","journal-title":"Innov. Gener. Antib. Drug Conjug."},{"key":"10.1016\/j.biopha.2025.118517_bib57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41423-023-01019-8","article-title":"Recent advancements in the B7\/CD28 immune checkpoint families: new biology and clinical therapeutic strategies","volume":"20","author":"Pulanco","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.118517_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2025.118517_bib59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/1078-0432.CCR-23-0433","article-title":"CDK4\/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis","volume":"30","author":"Nayyar","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/2326-6066.CIR-18-0881","article-title":"An artificial antigen-presenting cell delivering 11 immune molecules expands tumor antigen\u2013specific CTLs in ex vivo and in vivo murine melanoma models","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2025.118517_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/biomedicines8090327","article-title":"Antibody-based immunotherapy: alternative approaches for the treatment of metastatic melanoma","volume":"8","author":"Biteghe","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118517_bib62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2024.2302460","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer","volume":"20","author":"Cherifi","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2025.118517_bib63","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118517_bib64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/13543784.2024.2319317","article-title":"Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials","volume":"33","author":"Kiem","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2025.118517_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/pharmaceutics11020098","article-title":"A cell-level systems PK-PD model to characterize in vivo efficacy of ADCs","volume":"11","author":"Singh","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118517_bib66","first-page":"1","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L) 1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation","author":"Huang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2025.118517_bib67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/biomedicines12020369","article-title":"Breaking barriers: the promise and challenges of immune checkpoint inhibitors in triple-negative breast cancer","volume":"12","author":"Said","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118517_bib68","article-title":"Absence of CD47 in the tumor microenvironment modulates tumor metabolism and immunosuppressive signatures limiting breast cancer progression","author":"Stirling","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2025.118517_bib69","doi-asserted-by":"crossref","first-page":"01","DOI":"10.33140\/JCEI.09.01.03","article-title":"Addressing the challenges of PD-1 targeted immunotherapy in cancer treatment","volume":"9","author":"Mustafa","year":"2024","journal-title":"J. Clin. Exp. Immunol."},{"key":"10.1016\/j.biopha.2025.118517_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-62703-541-5_5","article-title":"Linker technologies for antibody\u2013drug conjugates","author":"Nolting","year":"2013","journal-title":"Antib. Drug Conjug."},{"key":"10.1016\/j.biopha.2025.118517_bib71","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2741\/1909","article-title":"Monoclonal antibody therapy","volume":"11","author":"O\u2019Mahony","year":"2006","journal-title":"Front Biosci."},{"key":"10.1016\/j.biopha.2025.118517_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biopha.2025.118517_bib73","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1016\/j.bmc.2005.04.084","article-title":"Recent advances in tumor-targeting anticancer drug conjugates","volume":"13","author":"Jaracz","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118517_bib74","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody\u2013drug conjugates","volume":"255","author":"Kovtun","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118517_bib75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature01451","article-title":"Regulated portals of entry into the cell","volume":"422","author":"Conner","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118517_bib76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbpa.2009.03.023","article-title":"Potent antibody drug conjugates for cancer therapy","volume":"13","author":"Senter","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118517_bib77","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2025.118517_bib78","series-title":"Taylor & Francis","first-page":"34","article-title":"Site-specific antibody drug conjugates for cancer therapy, MAbs","author":"Panowski","year":"2014"},{"key":"10.1016\/j.biopha.2025.118517_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of antibody-drug conjugates in cancer cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib80","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody\u2013drug conjugates","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biopha.2025.118517_bib82","doi-asserted-by":"crossref","first-page":"1492782","DOI":"10.3389\/fimmu.2024.1492782","article-title":"Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies","volume":"15","author":"Nix","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118517_bib83","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118517_bib84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3348\/kjr.2024.0195","article-title":"Imaging findings of complications of new anticancer drugs","volume":"26","author":"Jang","year":"2025","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.biopha.2025.118517_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.793831","article-title":"Improvement of PD-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mTOR inhibitor","volume":"12","author":"Bai","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118517_bib86","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2025.118517_bib87","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab\u2013maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib88","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.biopha.2025.118517_bib89","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of efflux pumps in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118517_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer Multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118517_bib91","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118517_bib92","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","volume":"27","author":"Gebhart","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib93","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Y cajal, J. Arribas, expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2025.118517_bib94","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib95","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy","volume":"20","author":"Phillips","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib96","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib97","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/cancers16152681","article-title":"Single-Domain antibodies as Antibody\u2013Drug conjugates: from promise to Practice\u2014A systematic review","volume":"16","author":"P\u00e9rez","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118517_bib98","article-title":"Resident immune cells of the liver in the tumor microenvironment","volume":"12","author":"Lu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118517_bib100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib101","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody\u2013drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118517_bib102","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118517_bib103","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib104","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib105","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody\u2013drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib106","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118517_bib108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","article-title":"Bispecific antibodies and antibody\u2013drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs","volume":"16","author":"Andreev","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118517_bib109","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib110","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT175","article-title":"Abstract CT175: safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study","volume":"83","author":"Yao","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118517_bib111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours","volume":"9","author":"Zhang","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.biopha.2025.118517_bib112","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib113","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2021.08.612","article-title":"329TiP KATE3: a phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1\u2013positive locally advanced or metastatic breast cancer","volume":"32","author":"Loi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118517_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx065","article-title":"An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression","volume":"109","author":"Schwarz","year":"2017","journal-title":"JNCI Journal National Cancer Institute"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:22:43Z","timestamp":1778541763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225007115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":114,"alternative-id":["S0753332225007115"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118517","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118517"}}